References
- Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis:
recent insights of molecular and cellular mechanisms and therapeutic
opportunities. J Scleroderma Rel Dis 2017;2(3):137e52 [Review
Article].
- Stochmal, A., Czuwara, J., Trojanowska, M., & Rudnicka, L. (2020).
Anti-nuclear Antibodies in Systemic Sclerosis : an Update. January
2019, 40–51.
- Patterson, K. A., Lester, S., Tan, J. A., Hakendorf, P., Rischmueller,
M., Zochling, J., Sahhar, J., Nash, P., Roddy, J., Hill, C., Nikpour,
M., Stevens, W., Proudman, S. M., & Walker, J. G. (2015).
Interpretation of an Extended Autoantibody Profile in a
Well-Characterized Australian Systemic Sclerosis ( Scleroderma )
Cohort Using Principal Components Analysis. 67(12), 3234–3244.
https://doi.org/10.1002/art.39316
- Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in
systemic sclerosis. Autoimmun. Rev. 2013;12(3):340–54.
- Kayser C, Frıtzler MJ. Autoantibodies in systemic sclerosis:
unanswered questions. Front Immunol 2015; 6: 1-6.
- LeRoy EC, Medsger TA, Jr. Criteria for the classification of early
systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
- Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati
I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini
G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M;
EUSTAR Group. Preliminary criteria for the very early diagnosis of
systemic sclerosis: results of a Delphi Consensus Study from EULAR
Scleroderma Trials and Research Group. Ann Rheum Dis. 2011
Mar;70(3):476-81. doi: 10.1136/ard.2010.136929. Epub 2010 Nov 15.
PMID: 21081523.
- Domsıc RT. Scleroderma: the role of serum au¬toantibodies in defining
specific clinical phenotypes and organ system involvement. Curr Opin
Rheuma¬tol 2014; 26: 646-52.
- Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification
criteria for systemic sclerosis: an American college of
rheumatology/European league against rheumatism collaborative
initiative. Ann Rheum Dis 2013;72:1747e55.
- LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA,
Jr., et al. Scleroderma (systemic sclerosis): Classification, subsets
and pathogenesis. J Rheumatol 1988; 15: 202-5.
- Nihtyanova, S. I., Sari, A., Harvey, J. C., Leslie, A., Derrett-smith,
E. C., Fonseca, C., Ong, V. H., & Denton, C. P. (2020). Using
Autoantibodies and Cutaneous Subset to Develop Based Disease
Classification in Systemic Sclerosis. 72(3), 465–476.
https://doi.org/10.1002/art.41153
- Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M,
Reichenberger F, et al. Frequency of disease-associated and other
nuclear autoantibodies in patients of the German network for systemic
Scleroderma: correlation with characteristic clinical features.
Arthritis Res Ther 2011;13(5):R172.
- Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper
T, Meyer W, Bogdanos DP, Sakkas LI. Disease-related autoantibody
profile in patients with systemic sclerosis. Autoimmunity. 2017
Nov;50(7):414-421. doi: 10.1080/08916934.2017.1357699. Epub 2017 Jul
27. PMID: 28749191.
- Didier K, Bolko L, Giusti D, et al. Auto-antibodies associated with
connec- tive tissue diseases: what meaning for clinicians? Front
Immunol 2018 ; 9:541 , .
- Medsger TA Jr. Natural history of systemic sclerosis and the
assessment of disease activity, severity, functional status, and
psychologic well-being. Rheum Dis Clin North Am. 2003
May;29(2):255-73, vi. doi: 10.1016/s0889-857x(03)00023-1. PMID:
12841294.
- Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A,
et al. 2013 classification criteria for systemic sclerosis: an
American College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum 2013;65: 2737–47.
- Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R,
Weinstein A, Weisman M, Mayes M, Collier D (1995) Inter and
intraobserver variability of total skin thickness score (modified
Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285
- Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE,
Desai A, Seibold JR (2008) Assessment of pulmonary arterial
hypertension in patients with systemic sclerosis: comparison of
noninvasive tests with results of right-heart catheterization. J
Rheumatol 35:458–465
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M,
Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS,
Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B,
Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O,
Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M,
Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS
Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Respir J. 2022 Aug 30:2200879. doi: 10.1183/13993003.00879-2022.
Epub ahead of print. PMID: 36028254.
- Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L. Scleroderma
renal crisis. J Rheumatol. 2014 Jun;41(6):1040-8. doi:
10.3899/jrheum.131210. Epub 2014 May 15. PMID: 24833760.
- Husson F, Josse J, Le S,Mazet J. Multivariate exploratory data
analysis and data mining with R: an R package for exploratory data
analysis. FactoMineR package version 1.25. 2013. URL:
http://factominer.free.fr.
- M. Inanc1, M. Birlik2, M. Onat3, Z. Ozbalkan4, F. Yargucu5, T.
Kasifoglu6, O.N. Pamuk7, S. Yavuz8, V. Yazisiz9, T. Senturk10, E.
Erken11, F. Syswatch Investigators12 Annals of the Rheumatic Diseases,
volume 68, supplement 3, year 2009, page 610
- Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in
systemic sclero- 894 sis. Autoimmun Rev 2013;12:340–354.
http://dx.doi.org/10.1016/j.autrev. 895 2012.05.011
- Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine.
2006 Oct;73(5):490-4. doi: 10.1016/j.jbspin.2006.01.022. Epub 2006 Jun
2. PMID: 16798048.
- Choi MY, Fritzler MJ. Progress in understanding the diagnostic and
pathogenic role of autoantibodies associated with systemic sclerosis.
Curr Opin Rheumatol. 2016 Nov;28(6):586-94. doi:
10.1097/BOR.0000000000000325. PMID: 27387266; PMCID: PMC5029444.
- Sibanda EN, Dube Y, Chakawa M, Mduluza T, Mutapi F. Systemic Sclerosis
in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory
Correlates. Front Immunol. 2021 Nov 9;12:679531. doi:
10.3389/fimmu.2021.679531. PMID: 34858387; PMCID: PMC8631108.
- Yayla ME, İlgen U, Düzgün N. An analysis of the relationship between
autoantibodies and clinical findings in patients with systemic
sclerosis. Turk J Med Sci. 2018 Feb 23;48(1):10-15. doi:
10.3906/sag-1708-67. PMID: 29479936.
- Nandiwada SL, Peterson LK,MayesMD, Jaskowski TD,Malmberg E, AssassiS,
et al. Ethnic differences in autoantibody diversity and hierarchy:
more clues from a US cohort of patients with systemic sclerosis. J
Rheumatol. (2016) 43:1816–24. doi: 10.3899/jrheum.160106
- Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et
al. South Australian Scleroderma Register: autoantibodies as
predictive biomarkers of phenotype and outcome. Int J Rheum Dis
2012;15:102–9
- Tan EM. Anti-nuclear antibodies in Scleroderma. Int J Dermatol
1981;20:569–73
- Nakamura RM, Tan EM. Recent advances in laboratory tests and the
significance of autoantibodies to nuclear antigens in systemic
rheumatic diseases. Clin Lab Med 1986;6:41–53
- Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D,
Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato
S, Takehara K, Kuwana M. Clinical usefulness of anti-RNA polymerase
III antibody measurement by enzyme-linked immunosorbent assay.
Rheumatology (Oxford). 2009 Dec;48(12):1570-4. doi:
10.1093/rheumatology/kep290. Epub 2009 Oct 5. PMID: 19808694
- Mahler M et al (2014) Current concepts and future directions for the
assessment of autoantibodies to cellular antigens referred to as
anti-nuclear antibodies. J Immunol Res 2014:315179
- Hudson M et al (2012) Clinical signifcance of antibodies to
Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50
- Hudson M, Ghossein C, Steen V, Scleroderma Renal Crisis, La Presse
Medicale’ (2021), doi: https://doi.org/10.1016/j.lpm.2021.104063
- Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M,
Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma
Research Group (CSRG); Australian Scleroderma Interest Group (ASIG);
Genetics versus Environment in Scleroderma Outcome Study (GENISOS),
Baron M, Fritzler MJ. Clinical correlates of monospecific anti-PM75
and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic
sclerosis subjects. Autoimmunity. 2015;48(8):542-51. doi:
10.3109/08916934.2015.1077231. Epub 2015 Aug 31. PMID: 26334795.
- Koschik II R. W., N. Fertig, M. R. Lucas, et al. 2012. Anti-PM-Scl
antibody in patients with systemic sclerosis. Clin. Exp. Rheumatol.
30(2 Suppl 71): S12–S16.
- Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P,
Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour
M, Stevens W, Proudman SM, Walker JG. Interpretation of an Extended
Autoantibody Profile in a Well-Characterized Australian Systemic
Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.
PMID: 26246178.
Table 1 . Demographic, clinical, and laboratory characteristics
of the SSc patients